Clinical Trials Logo

Clinical Trial Summary

There have been previous reports of using High-intensity focused ultrasound (HIFU) as a feasible thermal ablative treatment for relapsed Graves' disease. In recent years, radiofrequency ablation (RFA) has become another promising alternative for thermal ablation of benign thyroid nodules. RFA has the advantage of avoiding a surgical scar, organ preservation and being an ambulatory procedure. It utilizes a small caliber radiofrequency electrode, which is inserted into the thyroid gland percutaneously. The active tip of the RF electrode would induce frictional heat in the surrounding tissue, causing a thermal ablative effect. The direct application of energy of RFA to tissue is different from that in HIFU, in which energy is transmitted through the skin of the participants from the transducer. Studies of follow-up after RFA of Graves' disease have not been published. Given the previous successful experience with HIFU, the investigators would like to explore the feasibility, safety and efficacy of RFA as an alternative thermal ablation option for relapsed Graves' disease. Thus, the purpose of this prospective study is to assess the efficacy and safety of US-guided RFA for the treatment of relapsed Graves' disease.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06418919
Study type Interventional
Source The University of Hong Kong
Contact
Status Active, not recruiting
Phase N/A
Start date March 1, 2020
Completion date December 1, 2025

See also
  Status Clinical Trial Phase
Withdrawn NCT04708704 - Photodegraded Edible Food Dyes N/A
Not yet recruiting NCT06154382 - Eltroxin Administration to Patients With Extremely Low T4 Values in the Intensive Care Unit
Recruiting NCT03977207 - A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients N/A
Completed NCT02927119 - Serum Thyroglobulin as a Marker of Iodine Status During Pregnancy N/A